Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Mirkin

Showing results (41-50 of 104) with videos related to

Pageof 11
Sort By:
Menopause (New York, N.Y.)|June 13, 2019
The MATE survey: men's perceptions and attitudes towards menopause and their role in partners' menopausal transitionSharon J Parish, Stephanie S Faubion, Marc Weinberg, et al.
Journal of Women'S Health (2002)|July 10, 2020
Effects of Estradiol Dose and Serum Estradiol Levels on Metabolic Measures in Early and Late Postmenopausal Women in the REPLENISH TrialIntira Sriprasert, Howard N Hodis, Brian Bernick, et al.
Maturitas|August 4, 2009
Bazedoxifene/conjugated estrogens and quality of life in postmenopausal womenWulf Utian, Holly Yu, Joel Bobula, et al.
Menopause (New York, N.Y.)|November 19, 2014
Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables: a randomized placebo- and active-controlled trialSven O Skouby, Kaijie Pan, John R Thompson, et al.
Menopause (New York, N.Y.)|April 27, 2016
Efficacy and tolerability of bazedoxifene in Mexican women with osteoporosis: a subgroup analysis of a randomized phase 3 trialSantiago Palacios, Robert Williams, Sebastian Mirkin, et al.
Menopause (New York, N.Y.)|January 1, 2014
Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogensAndrew G Bushmakin, Lucy Abraham, JoAnn V Pinkerton, et al.
Menopause (New York, N.Y.)|September 21, 2016
Prescribing of FDA-approved and compounded hormone therapy differs by specialtyGinger D Constantine, David F Archer, Shelli Graham, et al.
Menopause (New York, N.Y.)|February 25, 2022
Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptomsMichael R McClung, Risa Kagan, Shelli Graham, et al.
Menopause (New York, N.Y.)|August 3, 2020
17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trialAndrew M Kaunitz, Diana Bitner, Ginger D Constantine, et al.
Menopause (New York, N.Y.)|August 22, 2018
WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer historySheryl A Kingsberg, Lisa Larkin, Michael Krychman, et al.
Pageof 11

Showing results (41-50 of 104) with videos related to

Sort By:
Pageof 11
Menopause (New York, N.Y.)|June 13, 2019
The MATE survey: men's perceptions and attitudes towards menopause and their role in partners' menopausal transitionSharon J Parish, Stephanie S Faubion, Marc Weinberg, et al.
Journal of Women'S Health (2002)|July 10, 2020
Effects of Estradiol Dose and Serum Estradiol Levels on Metabolic Measures in Early and Late Postmenopausal Women in the REPLENISH TrialIntira Sriprasert, Howard N Hodis, Brian Bernick, et al.
Maturitas|August 4, 2009
Bazedoxifene/conjugated estrogens and quality of life in postmenopausal womenWulf Utian, Holly Yu, Joel Bobula, et al.
Menopause (New York, N.Y.)|November 19, 2014
Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables: a randomized placebo- and active-controlled trialSven O Skouby, Kaijie Pan, John R Thompson, et al.
Menopause (New York, N.Y.)|April 27, 2016
Efficacy and tolerability of bazedoxifene in Mexican women with osteoporosis: a subgroup analysis of a randomized phase 3 trialSantiago Palacios, Robert Williams, Sebastian Mirkin, et al.
Menopause (New York, N.Y.)|January 1, 2014
Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogensAndrew G Bushmakin, Lucy Abraham, JoAnn V Pinkerton, et al.
Menopause (New York, N.Y.)|September 21, 2016
Prescribing of FDA-approved and compounded hormone therapy differs by specialtyGinger D Constantine, David F Archer, Shelli Graham, et al.
Menopause (New York, N.Y.)|February 25, 2022
Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptomsMichael R McClung, Risa Kagan, Shelli Graham, et al.
Menopause (New York, N.Y.)|August 3, 2020
17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trialAndrew M Kaunitz, Diana Bitner, Ginger D Constantine, et al.
Menopause (New York, N.Y.)|August 22, 2018
WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer historySheryl A Kingsberg, Lisa Larkin, Michael Krychman, et al.
Pageof 11